All data are based on the daily closing price as of October 6, 2025
o
Oneness Biotech
4743.TWO
2.15 USD
-0.10
-4.44%
Overview
Last close
2.15 usd
Market cap
1.03B usd
52 week high
5.38 usd
52 week low
1.56 usd
Target price
10.09 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
277.0978
Price/Book Value
2.9818
Enterprise Value
845.17M usd
EV/Revenue
229.217
EV/EBITDA
-91.0869
Key financials
Revenue TTM
3.69M usd
Gross Profit TTM
1.32M usd
EBITDA TTM
-20.32M usd
Earnings per Share
-0.13 usd
Dividend
N/A usd
Total assets
403.14M usd
Net debt
N/A usd
About
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.